investigational new drug (IND)
Applications and Submissions
Obtaining Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) is a critical step towards beginning your clinical trials in the United States. Getting here required hard work and a great Pre-IND Meeting strategy (which we can help manage), and you still need FDA approval on your IND application before you can ship your drug across state lines and begin clinical trials.
The sooner you can begin your clinical trials, the sooner your product will be on the market. To prevent any hiccups in this process, your final IND submission must be error-free and contain all required information including animal pharmacology and toxicology studies, manufacturer and investigator information, along with detailed protocols for your upcoming clinical trials.
No matter where you are in the IND application or submission process, our IND consultants can provide guidance to assist with the remaining steps.
Fill out the form on the right to contact our IND consultants to learn more and get started today!
What is an IND?
An Investigational New Drug Application (IND) is a request for authorization submitted by a Sponsor to the FDA so the Sponsor can conduct clinical trials for unapproved drugs. The purpose of an IND application is to allow Sponsors to start conducting clinical trials on humans, and approval to ship the drugs across state lines to conduct these trials.
Types of INDs
INDs fall into two categories:
Commercial IND: Commercial INDs are used when the Sponsor intends to bring the drug to the open market. This means commercial INDs can apply to drugs created by non-profit groups who intend to eventually put the drug on the open market. The application process and timeline for a Commercial IND is much longer and more complex than for a Research IND.
Research IND: Research INDs are used when the intention is to prove efficacy for a new indication of an already approved drug. Research IND applications are submitted by physicians, and with a process that is less complex than Commercial INDs. For example, Research INDs typically involve fewer investigators and are often done at a single testing site.
How to Submit an IND Application
Your IND application will request authorization from the FDA to administer an investigational drug/biological product to humans and must be approved before you transport your product across state lines to clinical sites. The requirements for an IND submission are complicated and can be hard to understand. For example, Commercial IND applications must be submitted through the FDA’s Electronic Submissions Gateway, while Research IND applications can be submitted in paper-form to the relevant address. This is just one example of the complexities within the IND application and submission process.
As such, working with an experienced FDA consultant will help assure you’re equipped and on track. ProPharma will work with you to make sure your IND application meets the FDA’s stringent IND filing requirements and contains all of the necessary components.
Partner with us!
IND Filing Requirements
Each IND application should include the following:
- Form FDA 1571 (IND application cover letter)
- Form FDA 1572 (Investigator's statement)
- Form FDA 3674 (Certification requirement & mandatory registration and reporting of results for applicable clinical trials through ClinicalTrials.gov.)
- Table of contents
- Introductory statement
- General investigational plan
- Investigator's brochure
- Protocol(s): study protocol(s), investigator data, facilities data, Institutional Review Board (IRB)
- Chemistry, manufacturing, and control (CMC) data, including environmental assessment or claim for the exclusion (assuming the draft of CMC information exists)
- Nonclinical: pharmacology and toxicology data
- Clinical: previous human experience
- Additional information to support the IND filing
Together, we will carefully review the IND application, and our staff will provide you with a final copy that is FDA ready. The IND application will go into effect 30 days after the FDA receives the application (unless subject to a clinical hold), or earlier if the agency notifies the Sponsor that clinical trials can begin.
Get Expert Guidance From an IND Consultant for Your Upcoming Submission
ProPharma will guide you through every step of the IND submission process and ensure your application is error-free to meet filing requirements and ensure a successful interaction with the FDA. To learn more about how ProPharma can help you develop a successful IND application for submission to the FDA, contact us today.
News & Insights
September 17, 2025
Decoding FDA’s Recent Advertising Enforcement Actions
Key takeaways from FDA’s latest enforcement letters which mark a major shift in advertising oversight and highlight new compliance risks for Sponsors.
September 10, 2025
FDA Launches Crackdown on Deceptive Drug Advertising
FDA’s new crackdown on deceptive drug advertising reshapes pharma marketing. Discover implications for sponsors, compliance strategies, and patient trust.
September 10, 2025
Creating an Effective Global Audit Strategy for Medical Device and Diagnostic Co...
Discover two distinct paths for creating a global audit strategy in medical device companies, focusing on harmonization and compliance efficiency ahead of FDA's 2026 QMSR changes.
July 8, 2025
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...
ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 21, 2024
ProPharma Appoints Brian Tuttle as Chief Financial Officer
ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
September 24, 2024
ProPharma Honored in the 2024 Clinical Trials Excellence Awards
ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.
September 15, 2025
Leading Technology Selection Decision Making
Discover how ProPharma enabled a leading global biopharma to overcome fragmented clinical sample management and outdated manual processes. Faced with disparate systems, off-site inventories, and...
September 9, 2025
Your Roadmap to European Drug Approval: The Complete Solution
Discover how ProPharma simplifies the complex journey to European drug approval by acting as a full-service Marketing Authorization Holder partner. From crafting regulatory strategies and...
September 3, 2025
Agility Meets Expertise: The ProPharma FSP Approach
Discover how ProPharma elevated the Functional Service Provider (FSP) Model by blending specialized expertise, agile resourcing, and innovative technology. By building dedicated teams, streamlining...
October 16, 2025
AI in Medical Information: Who Holds the Responsibility?
In Medical Information (MI) and beyond, key questions arise: Who ensures accuracy, compliance, and ethical use — individual contributors, leadership, pharma clients, or technology providers? And what...
September 23, 2025
Navigating the Review Process: Optimizing MLR Meetings for Speed and Compliance
Medical, Legal, and Regulatory (MLR) review meetings are a critical checkpoint in the promotional material approval process, but they’re often a source of bottlenecks, conflicting feedback, and...
September 17, 2025
The Path to Clarity – Unlocking the Power of Data Standards for Digital Transformation
In today’s data-driven R&D environment, fragmented and incompatible data can stall innovation. This webinar, led by experts from ProPharma and CSL Behring, reveals how robust data standards,...
News & Insights
September 17, 2025
Decoding FDA’s Recent Advertising Enforcement Actions
Key takeaways from FDA’s latest enforcement letters which mark a major shift in advertising oversight and highlight new compliance risks for Sponsors.
September 10, 2025
FDA Launches Crackdown on Deceptive Drug Advertising
FDA’s new crackdown on deceptive drug advertising reshapes pharma marketing. Discover implications for sponsors, compliance strategies, and patient trust.
September 10, 2025
Creating an Effective Global Audit Strategy for Medical Device and Diagnostic Co...
Discover two distinct paths for creating a global audit strategy in medical device companies, focusing on harmonization and compliance efficiency ahead of FDA's 2026 QMSR changes.
July 8, 2025
ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...
ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 21, 2024
ProPharma Appoints Brian Tuttle as Chief Financial Officer
ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
September 24, 2024
ProPharma Honored in the 2024 Clinical Trials Excellence Awards
ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.
September 15, 2025
Leading Technology Selection Decision Making
Discover how ProPharma enabled a leading global biopharma to overcome fragmented clinical sample management and outdated manual processes. Faced with disparate systems, off-site inventories, and...
September 9, 2025
Your Roadmap to European Drug Approval: The Complete Solution
Discover how ProPharma simplifies the complex journey to European drug approval by acting as a full-service Marketing Authorization Holder partner. From crafting regulatory strategies and...
September 3, 2025
Agility Meets Expertise: The ProPharma FSP Approach
Discover how ProPharma elevated the Functional Service Provider (FSP) Model by blending specialized expertise, agile resourcing, and innovative technology. By building dedicated teams, streamlining...
October 16, 2025
AI in Medical Information: Who Holds the Responsibility?
In Medical Information (MI) and beyond, key questions arise: Who ensures accuracy, compliance, and ethical use — individual contributors, leadership, pharma clients, or technology providers? And what...
September 23, 2025
Navigating the Review Process: Optimizing MLR Meetings for Speed and Compliance
Medical, Legal, and Regulatory (MLR) review meetings are a critical checkpoint in the promotional material approval process, but they’re often a source of bottlenecks, conflicting feedback, and...
September 17, 2025
The Path to Clarity – Unlocking the Power of Data Standards for Digital Transformation
In today’s data-driven R&D environment, fragmented and incompatible data can stall innovation. This webinar, led by experts from ProPharma and CSL Behring, reveals how robust data standards,...